 |
| Nick Leschly, CEO of bluebird bio |
Shares of Cambridge, MA-based bluebird bio ($BLUE) shot up after CEO Nick Leschly noted the looming arrival of early-stage data for its drug LentiGlobin, designed to treat the rare blood disorder beta thalassemia. Preliminary results will be presented in mid-June at the European Hematology Association Congress in Milan, Italy. There are about 15,000 patients in the U.S., according to the Boston Business Journal, who require blood transfusions to manage the disease. Story